What was the market valuation of the China daptomycin market in 2024?

The market valuation was $249.0 Million in 2024. Read More

What is the projected market valuation for the China daptomycin market by 2035?

The projected market valuation for 2035 is $375.0 Million. Read More

What is the expected CAGR for the China daptomycin market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 3.79%. Read More

Which companies are the key players in the China daptomycin market?

Key players include Cubist Pharmaceuticals, Merck & Co., AstraZeneca, Baxter International, Sandoz, Teva Pharmaceutical Industries, Pfizer, and Novartis. Read More

What were the market values for complicated skin structure infections in 2024?

The market value for complicated skin structure infections was $149.0 Million in 2024. Read More

What is the projected market value for bacteremia in 2035?

The projected market value for bacteremia by 2035 is $150.0 Million. Read More

How does the market for pediatric daptomycin compare to adult daptomycin in 2024?

In 2024, the market value for pediatric daptomycin was $49.0 Million, whereas adult daptomycin was valued at $200.0 Million. Read More

What are the market values for different strengths of daptomycin in 2024?

In 2024, the market values were $100.0 Million for 350mg and $149.0 Million for 500mg. Read More

What is the anticipated growth trend for the adult age group segment in the China daptomycin market?

The adult age group segment is expected to grow from $200.0 Million in 2024 to $300.0 Million by 2035. Read More

How does the market for daptomycin in China reflect on the global pharmaceutical landscape?

The growth in the China daptomycin market may indicate a broader trend of increasing demand for advanced antibiotics in emerging markets. Read More

China Daptomycin Market

China Daptomycin Market Research Report By Indication (Complicated Skin Structure Infections, Bacteremia), By Age Group (Pediatric, Adult) and By Strength (350mg, 500mg) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.79%

2024 Market Size

$ 249 Million

2035 Market Size

$ 375 Million

Healthcare ● Updated February 2026 Report ID: MRFR/HC/49585-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Indication (USD Million)
  1. 4.1.1 Complicated skin structure infections
  2. 4.1.2 Bacteremia
2. 4.2 Chemicals and Materials, BY Age Group (USD Million)
  1. 4.2.1 Pediatric
  2. 4.2.2 Adult
3. 4.3 Chemicals and Materials, BY Strength (USD Million)
  1. 4.3.1 350mg
  2. 4.3.2 500mg
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Cubist Pharmaceuticals (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co. (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Baxter International (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sandoz (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Teva Pharmaceutical Industries (IL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY INDICATION
3. 6.3 CHINA MARKET ANALYSIS BY AGE GROUP
4. 6.4 CHINA MARKET ANALYSIS BY STRENGTH
5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
11. 6.11 CHEMICALS AND MATERIALS, BY INDICATION, 2024 (% SHARE)
12. 6.12 CHEMICALS AND MATERIALS, BY INDICATION, 2024 TO 2035 (USD Million)
13. 6.13 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 (% SHARE)
14. 6.14 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 TO 2035 (USD Million)
15. 6.15 CHEMICALS AND MATERIALS, BY STRENGTH, 2024 (% SHARE)
16. 6.16 CHEMICALS AND MATERIALS, BY STRENGTH, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY AGE GROUP, 2025-2035 (USD Million)
  3. 7.2.3 BY STRENGTH, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Daptomycin Market Segmentation

China Daptomycin Market By Indication (USD Million, 2025-2035)

Complicated skin structure infections
Bacteremia

China Daptomycin Market By Age Group (USD Million, 2025-2035)

Pediatric
Adult

China Daptomycin Market By Strength (USD Million, 2025-2035)

350mg
500mg

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”